Skip to main content
18 views

DSIP (Delta Sleep-Inducing Peptide)

Delta sleep-inducing peptide for improved sleep quality

DSIP (Delta Sleep-Inducing Peptide) molecular structure

Overview

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid peptide first discovered in rabbit brains during sleep. Unlike sleeping pills that sedate you, DSIP appears to work by normalizing your sleep patterns. **How is it different from sleeping pills?** Traditional sleep medications force you to sleep but often disrupt natural sleep architecture. DSIP seems to restore normal sleep cycles, particularly promoting delta wave sleep — the deep, restorative stage where your body does most of its repair work. **What the research shows:** • Promotes delta wave (deep) sleep without sedative hangover • May help normalize disrupted circadian rhythms • Could reduce stress-induced sleep disturbances • Shows pain-modulating properties • May influence stress hormone regulation **Potential uses:** Researchers have explored DSIP for insomnia, jet lag, chronic pain, and even opioid withdrawal — though clinical evidence remains limited. **How it works:** DSIP appears to modulate GABA receptors, serotonin systems, and stress hormones, but its exact mechanism isn't fully understood. **Typical use:** Administered via injection, often before bedtime. **Important to know:** DSIP is not FDA-approved and research, while intriguing, is limited. Most studies are from the 1980s-90s. --- **Sources:** Schoenenberger GA, et al. (1977) Proceedings of the National Academy of Sciences | Graf MV, et al. (1986) Neuroscience & Biobehavioral Reviews

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

Delta sleep-inducing peptideDSIPWAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)

Status: Research compound - Neuropeptide

CAS62568-57-4
PubChem68816

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Sleep regulation / insomniaNeuroendocrine (HPA-axis) modulationChronic painOpioid-withdrawal support

Available Evidence

Human

A double-blind study in chronic insomniacs (Neuropsychobiology 1992) reported improved sleep with DSIP, and an earlier Lancet report (1981) described improved sleep in insomniacs. Small studies also reported reduced pain episodes in chronic pain patients (Eur Neurol 1984) and use as an adjunct in opioid detoxification; this clinical literature is old, small, and never replicated in modern trials.

Animal

Rodent studies show DSIP increases delta-wave sleep and modulates stress-related endocrine responses (e.g., corticosterone), supporting a neuroendocrine role beyond sleep.

In Vitro

DSIP shows no classic sedative pharmacology; laboratory work has focused on rapid enzymatic degradation in plasma (very short half-life) and receptor-binding/neuroendocrine assays.

Uncertain

The peptide is rapidly degraded and its half-life is short, and reproducible sleep-promoting efficacy in modern controlled trials has not been established; most clinical evidence dates from the 1980s–1990s and is methodologically limited.

Key Studies & Findings

3 studies

Benefits & Effects

20 documented

Recovery optimization

anecdotal

Stress reduction

anecdotal

Circadian rhythm regulation

anecdotal

Sleep Enhancement: Enhances non-REM and REM architecture

clinical

Neuroprotection: Stroke recovery when given during reperfusion

clinical

Induces physiological sleep

Reduces stress

Normalizes blood pressure

Improves hormone levels.

Deep sleep enhancement

anecdotal

Sleep quality improvement

anecdotal

Neurological support

anecdotal

Four consecutive injections completely normalized disturbed sleep in insomniacs

clinicalsleep

Improved alertness during wakefulness

clinicalcognitive

Better stress tolerance and coping

clinicalstress

Motor function recovery after stroke

preclinicalneurological

Induces physiological sleep

Reduces stress

Normalizes blood pressure

Improves hormone levels.

Side Effects & Safety

9 reported

Interaction

Avoid: Stimulants

Interaction

Avoid: Stimulants

Good tolerability; bell-shaped dose-response curves noted

mildrare

Paradoxical anesthesia effect

mild

Severe side effect

severeFatal when misadministered

Onset: Immediate

Management: ONLY during reperfusion, NOT during ischemia

Early reports suggest mild nausea

mildUncommon

Headache

mildUncommon

Fatigue

mildUncommon

Rare unknown long-term effects

severeRare

Limitations & Open Questions

All clinical data are decades old, small, and unreplicated; no modern randomized trials confirm sleep, pain, or metabolic benefits. Peptide instability (short half-life) and non-standardized formulations make the clinical literature hard to interpret.

Pharmacology

A nine-amino-acid endogenous peptide with a very short plasma half-life (rapid enzymatic degradation), historically administered intranasally or intravenously in clinical studies; effects are linked to delta-sleep promotion and neuroendocrine (stress-axis) modulation rather than direct receptor-driven sedation.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

100-300mcg before bed

Route: SC/IV
Half-life: 2 hours

Research Protocols

Sleep Enhancement

Dose
100-200mcg
Frequency
Once nightly
Route
Subcutaneous

Chronic Pain

Dose
250-300mcg
Frequency
Daily
Route
IV or SubQ

Stress Management

Dose
150mcg
Frequency
Evening
Route
Subcutaneous

Withdrawal Support

Dose
200-300mcg
Frequency
Twice daily
Route
IV preferred

Athletic Recovery

Dose
100-150mcg
Frequency
Post-training
Route
Subcutaneous

Research protocols are for educational purposes only. Always consult qualified medical professionals.

Frequently Asked Questions

Is DSIP approved as a sleep medication?

No. DSIP is not an approved drug; it is sold as a research peptide, and the supporting clinical studies are old and small.

Does DSIP work like a sleeping pill?

No — it is not a sedative. Research suggests it modulates sleep architecture (delta/deep sleep) and stress hormones, but modern confirmatory trials are lacking.

Research Citations

Related Resources

Quick Facts

Formula

C35H48N10O15

Molecular Weight

848.82

Sequence

WAGGDASGE

Mechanism

Sleep quality enhancement and stress management peptide

Safety Information

Research compound only. Limited human safety data available.

View All Peptides